Amidst the perpetual and turbulent innovation and adoption of tech-oriented ecosystems by the world, the looming threats are overshadowing them at a much faster and smatter pace. It is not a topic of discussion anymore how much tech-dependent the whole world has become, however, it certainly begs other branches for discourse; cyber threats, hacking, ransom […]
TOKYO, Mar 25, 2022 - (JCN Newswire) - JTOWER Inc. ("JTOWER") and NTT DOCOMO, INC. ("DOCOMO") have announced today that the companies have decided to enter into the master transaction agreement with the aim of promoting Infra-Sharing of DOCOMO's existing towers. The contract will enable the companies to make a transaction in which 6,002 telecommunications towers (maximum) owned by DOCOMO to be transferred to JTOWER for 106.2 billion yen (maximum) and DOCOMO will lease these towers from JTOWER ("the Transaction").
Image of a telecommunications tower
Aims of both companies
JTOWER positions the purchase of existing telecommunications towers owned by telecommunications companies and the promotion of Infra-Sharing by attracting new tenants to these towers (carve-out) to be one of the key growth strategies. The Transaction will greatly expand its business foundation as a tower sharing operator.
DOCOMO is working to build an economical 5G network by promoting Infra-Sharing and the Transaction will enable further streamlining of network operations. Future Initiatives
The companies plan to make the transfer of the towers where conditions have been met and JTOWER will strengthen its efforts to attract new tenants, such as telecommunications companies, including mobile network operators. Through these efforts, both companies aim to realize more efficient capital investments and operating expenses for the tenants of these towers and promote the early deployment of 5G network. Furthermore, the companies will contribute to the realization of a sustainable society by reducing environmental impact through the effective use of existing infrastructure.
JTOWER and DOCOMO will continue to strengthen collaboration in the field of Infra-Sharing and work to resolve social issues that contribute to the telecommunications industry.
JTOWER Inc. was founded in June 2012 as the first Infra-Sharing company in Japan. Centered on indoor Infra-Sharing solutions that consolidate the mobile networks inside the building, we provide a wide range of services including 5G that contribute to the future. https://en.jtower.co.jp/
About NTT DOCOMO
NTT DOCOMO, Japan's leading mobile operator with over 83 million subscriptions, is one of the world's foremost contributors to 3G, 4G and 5G mobile network technologies. Beyond core communications services, DOCOMO is challenging new frontiers in collaboration with a growing number of entities ("+d" partners), creating exciting and convenient value-added services that change the way people live and work. Under a medium-term plan toward 2020 and beyond, DOCOMO is pioneering a leading-edge 5G network to facilitate innovative services that will amaze and inspire customers beyond their expectations. https://www.docomo.ne.jp/english/.
Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comJTOWER Inc. and NTT DOCOMO, INC. have announced today that the companies have decided to enter into the master transaction agreement with the aim of promoting Infra-Sharing of DOCOMO's existing towers.
HONG KONG, Mar 25, 2022 - (ACN Newswire) - Kindstar Globalgene Technology, Inc. ("Kindstar Globalgene" or the "Company", together with its subsidiaries, collectively the "Group"; stock code: 9960.HK), a leading independent esoteric clinical testing service provider in China, today announced its audited annual results for the year ended 31 December 2021 ("2021" or the "Year").
During the period under review, the Group recorded total revenue of RMB930.67 million, representing a year-on-year increase of 4.4%. Revenue from non-COVID-19-related testing services was RMB868.57 million, an increase of 12.3%. The Group's consolidated gross profit was up by 5.4% year-on-year to RMB485.77 million, while the consolidated gross profit margin rose by 0.5% year-on-year to 52.2%. Cash and cash equivalents amounted to RMB1,796.7 million, a growth of 113.6% year-on-year. The non-COVID-19-related testing services segment recorded results of RMB197.18 million, an increase of 17.5% year-on-year. The Board has resolved not to distribute a dividend for FY2021.
Focused on specialty esoteric testing services and vigorously developed related services in six major specialty areas
Since its inception in 2003, the Group has been focusing on esoteric clinical testing services and is one of the first companies in China entering the esoteric testing service industry. During the period under review, the Group covered more than 3000 hospitals, in which over 60% are Class III hospitals, added three new laboratories and its esoteric testing volume exceeded 1.68 million, with positive growth in all six major esoteric testing specialty areas.
-- Hematology testing: The Group introduced 50 new testing items and added the Shanghai Xinnuo Baishi Medical Laboratory. During the period, the Group achieved revenue of RMB535.27 million and segment results of RMB152.57 million, representing a year-on-year increase of 14% and 15.7%, respectively. -- Neurology testing: The Group launched six new projects covering diseases such as Alzheimer's disease and myasthenia [gravis] and also added 143 partnering Class III hospitals. The Group recorded revenue of RMB89.85 million and segment results of RMB14.06 million during the period, a year-on-year increase of 18.2 and 11.6%, respectively. -- Maternity-related testing: The Group added the diagnosis of gestational syndromes during the period, and recorded revenue of RMB52.25 million and segment results of RMB3.55 million, representing a year-on-year increase of 0.2% and 0.5%, respectively. -- Genetic disease and rare disease testing: During the period, the Group realized revenue of RMB43.50 million and segment results of RMB5.43 million, representing a year-on-year increase of 20.2% and 126.4%, respectively. Sales of multiple steroid hormone tests doubled year-on-year. -- Infectious disease testing: The Group introduced 28 new testing items and added the Wuhan Kindstar Zhenyuan Medical Laboratory, achieving revenue of RMB51.97 million and segment results of [RMB]9.78 million during the period, representing a year-on-year increase of 3% and 33.2%, respectively. -- Oncology testing: The Group launched new testing service items for various types of cancer, including intestinal cancer, cervical cancer, bladder cancer and liver cancer, achieving revenue of RMB8.62 million and segment results of RMB0.83 million during the period, 13.4% and 82.5% higher than the same period last year. -- Others: The Group added more than 20 scientific research service projects in the areas of research services, CRO and new testing services, achieving revenue of RMB19.46 million and segment results of RMB5.99 million during the period, representing a year-on-year growth of 36.1% and 35.1%, respectively.
Persistent R&D investment to develop and expand new specialty esoteric testing business lines
As at 31 December 2021, the Group's R&D expenses amounted to RMB90.33 million, a year-on-year increase of 20.0%.The Group had 112 new R&D projects, 17 patents were pending or granted and 23 scientific research articles were published throughout the year. During the period under review, the Group stepped up its efforts in promoting the development of specialty esoteric testing services in China and expanding the scope of such services to cover cardiovascular diseases, ophthalmology, rheumatology and immunology.
-- Cardiovascular diseases: The Group focused on the R&D of biomarkers for cardiovascular diseases such as coronary heart disease, acute myocarditis and acute myocardial infarction. It also conducted verification studies on the clinical value of biomarkers. -- Ophthalmology: The Group actively explored opportunities in ophthalmic structured esoteric testing services and its R&D covered testing solutions for hereditary oculopathy, infectious oculopathy and autoimmune oculopathy. -- Rheumatology and immunology: The Group began the initial development of six types of disease and drug detection projects, covering sicca syndrome, rheumatoid arthritis, ankylosing spondylitis, gout, antiphospholipid syndrome and allopurinol detection.
Entered the IVD reagents field and optimized immune repertoire deployment
Wuhan Haixi Life Science Technology Co., Ltd., which the group owns a controlling stake, is a high-tech enterprise based on the R&D, manufacturing and sales of esoteric testing reagents providing systematic, comprehensive "high-precision and cutting edge" testing reagent products. The Group's main products, namely reagent kits for JAK2 genes and V617F mutations (PCR-fluorescent probe method) and reagent kits for leukemia fusion genes qualitative testing (PCR-fluorescent probe method) will enter the clinical trial stage of NMPA registration. During the period under review, the Group established its business presence in the field of IVD reagent kits in the upstream industry chain by holding shares in Wuhan Haixi Life Science Technology Co., Ltd.
As an important next-generation sequencing technology, the immune repertoire sequencing technology may bring disruptive changes to the industry in the future. During the period under review, the Group established Wuhan Kindstar Biotechnology Co., Ltd., which will focus on the application and development of the immune repertoire technology in multiple disciplines and explore the biopharmaceutical and immunotherapy pathways. In addition, to further improve its immune repertoire layout, the Group invested in Shenzhen Neoimmune Co., Ltd., a leading immune repertoire enterprise in China. Looking ahead, the two parties will commence strategic cooperation in the immune repertoire segment.
Strategy and Prospects
The Group will continue to consolidate its leading position in esoteric hematology testing in China and replicate its successful experience in hematology to expedite the growth of its specialty esoteric testing business in areas such as genetic diseases, rare diseases, infectious diseases, oncology and neurology. In the next three to five years, the Group will enter several new areas of specialty esoteric testing. At the same time, the Group is also committed to building strong relationships with a wide range of participants in the clinical esoteric testing industry (including doctors, hospitals, pharmaceutical companies, contract research institutions, academic institutions and regulatory agencies), deepening existing strategic partnerships, and expanding the existing cooperation network. Since its listing, the Group has attached great importance to opportunities for horizontal and vertical integration in the industrial chain. In the future, the Group will steadily achieve a strategic and forward-looking layout through investment, integration and empowerment, in order to boost its growth.
Huang Shiang, Chairman and Chief Executive Officer of Kindstar Globalgene, expressed full confidence in the future of China's esoteric clinical testing industry. He said, "Due to increasing public health awareness and an aging population in China, the demand for clinical tests has continued to increase. In recent years, China's esoteric clinical testing market has been growing faster than its routine testing market, and the Company has strived to develop and introduce advanced technologies to meet the enormous unmet medical demand in the country. Looking ahead, we will actively overcome the various uncertainties caused by the COVID-19 pandemic, while continuing to work hard to maintain the steady growth of our existing esoteric clinical tests, and develop and launch new services in specialty areas, thereby contributing to the precise diagnosis and advancement of treatments in specialty areas in China."
About Kindstar Globalgene Technology, Inc. Kindstar Globalgene Technology, Inc. ("Kindstar Globalgene" or the "Group"; stock code: 9960.HK) is a leading independent esoteric clinical testing service provider and a major provider of hematology esoteric testing services in China. It has built a comprehensive testing portfolio, a broad hospital network and advanced technology platforms and also boasts the largest esoteric testing portfolio among all independent esoteric testing providers in China, with more than 3,500 tests on its service menu and offering one of the most extensive hematology testing portfolios worldwide, including over 2,300 testing items in the field. The Group primarily targets specialty areas with substantial growth potential or that can create significant synergies with its esoteric hematology testing services, including genetic diseases and rare diseases, infectious diseases, oncology and neurology. The Group was listed on the Main Board of the Hong Kong Stock Exchange on 16 July 2021. Over the past 18 years, the Company has developed more than 1,100 testing items entirely in-house, and introduced approximately 2,400 testing items developed by or under license from third parties. The Group serves more than 3,000 hospitals in China, of which more than 1,500 are Class III hospitals, including all of the top 20 hospitals in the nation. The Group's mission is to offer a broad range of high-quality specialty testing services to patients and physicians worldwide, and to promote the application of precision diagnostics and medicine.
Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comKindstar Globalgene Technology, Inc. ("Kindstar Globalgene" or the "Company", together with its subsidiaries, collectively the "Group"; stock code: 9960.HK), a leading independent esoteric clinical testing service provider in China, today announced its audited annual results for the year ended 31 December 2021 ("2021" or the "Year").
50% Revenue Growth Year-over-Year and 188% Increase in Cash Provided by Operations in 2021 National Advisory & Brokerage Clients in New State Markets Set the Stage for Company Expansion SCOTTSDALE, Ariz.–(BUSINESS WIRE)–$ZDPY #Brokerage–Zoned Properties®, Inc. (the “Company”) (OTCQB: ZDPY), a leading real estate development firm for emerging and highly regulated industries including legalized cannabis, today […]
If you want to be a part of the NFT space, then you should visit NFT marketplaces where you can trade NFTs ranging from music to art to assets of the virtual world. There are dozens of marketplaces and some marketplaces cater to specific sectors. What things should you look for in an NFT marketplace before picking which one to utilize and which are the top NFT marketplaces? This article covers top NFT marketplaces in detail. OpenSea OpenSea is the biggest decentralized peer-to-peer marketplace for buying, selling, and trading rare digital assets, such as gaming assets, collectibles, and art which runs on the Ethereum blockchain. In reality, OpenSea bills itself as the world’s largest marketplace for digital assets, claiming to have the best pricing on new NFTs and a wide choice of available NFTs in over 200 categories. Digital art, decentralized domain names, trading cards, virtual worlds, digital collectibles, sports NFTs, utility NFTs, you name it, all of these items can be traded on OpenSea. Cryptopunks, Axie Infinity, Gods Unchained, CryptoKitties, SuperRare, and other popular NFT projects use it as their primary platform. Rarible Rarible is a non-profit marketplace for selling single works of art and collections. Sports, gaming, media corporations, and artists launching collections of work are attracted to Rarible due to its decentralized nature. It is a community-owned platform that encourages decentralization. It has its token, RARI, and the platform’s users get to vote on any platform changes and participate in governance. For example, Adobe has worked with Rarible to secure artists’ work and develop unique NFTs. Rarible uses Flow, Tezos, and Ethereum. You may choose which token to use when you mint your NFT, and you can share your search options with OpenSea. The topic of which blockchain to use is intriguing. The most popular blockchain for NFT minting is Ethereum, although it has a significant carbon footprint and hefty gas prices. Tezos has modest gas expenses (about $0.50). However, it’s aimed towards artists releasing compilations. Flow uses lazy minting, which means creators pay almost no fees, and it’s a proof-of-stake blockchain, meaning it has a much lighter carbon footprint than Ethereum. Nifty Gateway Nifty Gateway has helped some of the most well-known digital artists, including Beeple and singer/musician Grimes, sell their music. It’s a cryptocurrency exchange-backed art curation platform (controlled by the Winklevoss twins). The NFTs, sometimes known as Nifties, are Ethereum-based. Nifty Gateway hosts any NFTs purchased, which means the NFTs aren’t held in your wallet but rather on Nifty Gateway’s servers. NFT collectors may not like this feature, who like more flexibility while investing in art. Purchases on Nifty Gateway can also be done in fiat currency(e.g., US dollars) without the need of purchasing cryptocurrency. Super Rare The Super Rare platform gives more of a gallery feel to the NFT space. It’s an NFT marketplace that prioritizes artistic intent and credibility above meme-friendly art. You won’t find any celebrity NFTs in SuperRare. It is said to accept only 1% of all applicants, which may sound snobbish, but if you are selected, you will be included in a catalogue of well-curated and intriguing artworks. SuperRare has the atmosphere of a high-end gallery, which is heightened by a rule that allows its artists to mint one of their originals — no Editions here. This indicates that the pieces are more scarce and so rare, as the term implies. It is one of the top NFT marketplaces for serious art and artists, which is incredibly uncommon in the NFT space. Top Shot The NBA and the Women’s National Basketball Association have teamed with NBA Top Shot, a fan-driven marketplace, to sell collectible moments and art based on the world’s most famous NBA sport and women’s basketball league. Go to the fastest-growing marketplace instead of going to Amazon for your next sports present. Firstly, you need to create an account with the NBA’s Top Shot to purchase an NFT. Top Shot is a closed marketplace that only allows you to buy and sell things on their site, and it was built on the Flow Blockchain by Dapper Labs. Some memorabilia can be purchased for as little as a few dollars. Magic Eden Magic Eden is a Solana blockchain-based decentralized application. The blockchain allows users to generate and manage non-fungible tokens. NFTs can be used for various things, such as digital collectibles, game assets, and more. The following are some of the desirable characteristics of Magic Eden: Launchpad: This capability is exclusive to Magic Eden and allows users to construct NFTs in minutes without using any other software. The platform now only accepts a small number of projects; however, this is likely to change. Future Launches: Rather than wasting time looking for your favourite creator’s next NFT drop, Magic Eden provides a curated list of upcoming launches so you … Continued
Payment gateway solutions are investing more heavily in AI technology these days. Some of the leading companies like PayPal have discovered that payment AI technology can be tremendously useful. PayPal has consistently actually been 10-20% more effective at preventing fraud in real-time through the use of AI. There are many other reasons that AI technology […]
The Japanese CoinCheck exchange will list on NASDAQ in a $1B SPAC merger with Thunder Bridge Capital Partners as we are reading furhter in today’s latest cryptocurrency news. The Coincheck exchange will list on NASDAQ as it announced plans to go public in the US by entering into a merger agreement with Thunder Bridge Capital […]
Read Time: 5minutes The Ethereum Blockchain is having scalability issues. So many decentralized apps are being built on the Ethereum network. Ethereum can only process fifteen transactions per second, and with a lot of Dapps coming into the network, the number of transactions will increase. This leads to network congestion and an increase in gas taxes. This particular …